article thumbnail

Available for Preorder: The 2022 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Drug Channels

On March 15, 2022, Drug Channels Institute will release The 2022 Economic Report on U.S. We are providing you with the opportunity to preorder this thoroughly updated, revised, and expanded 2022 edition at special discounted prices. Special preorder and launch pricing discounts will be valid through March 28, 2022.

article thumbnail

FDA’s September 2022 NPRMs: What They Mean for Academia and Industry

Advarra

On September 28, 2022, the Food and Drug Administration (FDA) released two Notices of Proposed Rulemaking (NPRM). In addition to the harmonization goal, these additional elements help modernize the regulations with current scientific and participant expectations. . Again, this is similar to what HHS regulations currently permit. .

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A comprehensive review on the research progress of PTP1B inhibitors as antidiabetics

Chemical Biology and Drug Design

PTP1B is a negative insulin signaling pathway regulator; hence, inhibiting PTP1B increases insulin sensitivity, glucose absorption, and energy expenditure. PTP1B is a negative insulin signaling pathway regulator; hence, inhibiting PTP1B increases insulin sensitivity, glucose absorption, and energy expenditure.

Research 100
article thumbnail

The Year (and a Half) in Review: 2022

KIF1A

As families, scientists, doctors and our friends around the world navigated the challenges of 2022, the KIF1A.ORG community worked together to reach new heights. Over 162 new families from around the world joined our community since January 2022. What a year! As this community grows, so does our army of advocates and supporters.

article thumbnail

Drug-induced long QT syndrome: Concept and non-clinical models for predicting the onset of drug-induced torsade de pointes in patients in compliance with ICH E14/S7B guidance [Minireview]

ASPET

In 2022, ICH released E14/S7B Q&As (Stage 1), emphasizing a "double negative" nonclinical scenario for low-risk compounds. This review details the onset mechanisms of drug-induced TdP, including I Kr inhibition, pharmacokinetic factors, autonomic regulation and reduced repolarization reserve.

article thumbnail

Finalizing the Quality Management System Regulation – A High Priority for End of 2023

FDA Law Blog: Biosimilars

By Véronique Li, Senior Medical Device Regulation Expert — Earlier this year, neither the Quality System Regulation (QSR) nor the Quality Management System Regulation (QMSR) were referenced in the semiannual regulatory agenda.

article thumbnail

FDA Programs to Support Advanced Manufacturing: Where Innovation Meets Regulation

The Premier Consulting Blog

To support this, the Innovative Technologies and Advanced Manufacturing Hub (I-TEAM Hub) was created. Advanced Manufacturing Technologies Designation Program The provision for the advanced manufacturing technologies designation program was enacted under the Food and Drug Omnibus Reform Act of 2022 (FDORA).

FDA 52